United States – Goodwin Represents Nimbus Therapeutics In Research Collaboration And License Agreement With Lilly For Novel Oral Obesity Treatment For Up To $1.3 Billion
GP
Goodwin Procter LLP
At Goodwin, we partner with our clients to practice law with integrity, ingenuity, agility, and ambition. Our 1,600 lawyers across the United States, Europe, and Asia excel at complex transactions, high-stakes litigation and world-class advisory services in the technology, life sciences, real estate, private equity, and financial industries. Our unique combination of deep experience serving both the innovators and investors in a rapidly changing, technology-driven economy sets us apart.
The Life Sciences team advised Nimbus Therapeutics, LLC (“Nimbus Therapeutics” or “Nimbus”) on entering a multi-year research collaboration and exclusive, worldwide license agreement with Eli Lilly and Company (“Lilly”) to develop a novel oral treatment f
United States
To print this article, all you need is to be registered or login on Mondaq.com.
TheLife Sciencesteam advised Nimbus Therapeutics,
LLC (“Nimbus Therapeutics” or “Nimbus”) on
entering a multi-year research collaboration and exclusive,
worldwide license agreement with Eli Lilly and Company
(“Lilly”) to develop a novel oral treatment for obesity
and other metabolic diseases. Under the terms of the collaboration,
Nimbus is eligible to receive upfront and near-term milestone
payments totaling $55 million, with eligibility to receive up to
approximately $1.3 billion in total including development,
commercial, and sales milestone payments, as well as tiered
royalties on global net sales.
Nimbus
Therapeuticsis a structure-based drug discovery company
developing breakthrough small molecule medicines through
AI-enhanced computational chemistry. Nimbus pursues well-validated
but difficult-to-drug targets with high potential to transform
patients’ lives. The company advances promising research based
on a unique strategy that combines leading-edge computational
technologies with a tailored array of machine learning-based
predictive modeling approaches. Nimbus’ pipeline includes
NDI-219216, a Werner syndrome helicase (WRN) inhibitor in Phase 1/2
development for microsatellite instability high (MSI-H) tumors, a
salt-inducible kinase 2 (SIK2) inhibitor advancing toward
first-in-human studies for inflammatory and autoimmune diseases,
and multiple preclinical programs in oncology, immunology, and
metabolic diseases. The company is headquartered in Boston,
Mass.
The Goodwin deal team was led bySarah SolomonandEmily Bemanand consisted ofBill Collins,Dan Karelitz,Susan Lee,Matt Wetzel, andJustin Pierce.
For more information on the deal, please read thepress release.
link
